Clinical trials
Renal Cell Carcinoma clinical trials
Below are recruiting renal cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 529 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04299646RecruitingPhase 2
Stereotactic radiation for limited spread in kidney cancer
This trial tests whether targeted, high-precision radiation (stereotactic radiotherapy) can control a small number of growing kidney cancer metastases while you continue systemic treatment. It may help people who have “oligoprogressive” disease, where only 1–3 spots are getting worse.
AlbiAges 18 years+ - NCT04510597RecruitingPhase 3
Immunotherapy plus surgery versus immunotherapy alone for kidney cancer
This study tests whether adding surgery to remove the kidney improves outcomes compared with continuing immunotherapy without surgery. It is for people with metastatic kidney cancer whose disease has not worsened after initial immunotherapy.
Birmingham, AlabamaAges 18 years+ - NCT04198766RecruitingPhase 1/Phase 2
New OX40 immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
Duarte, CaliforniaAges 18 years+ - NCT04113486Recruiting
NMAP protein in new kidney or liver tumors
This study looks at a protein called NMAP in people who have a new kidney or liver mass that will be surgically removed. It helps researchers understand how this protein relates to cancer and might lead to better tests or treatments in the future.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04053855Recruiting
Check urine for kidney cancer signals before or after surgery
This study looks for tiny substances in urine (called exosomes) to see if they can help identify clear cell kidney cancer. It compares urine samples from people having planned kidney surgery with people having surgery without a scheduled plan.
Saint-EtienneAges 18 years+ - NCT03972657RecruitingPhase 1/Phase 2
Testing a new prostate and kidney cancer drug with immunotherapy
This early trial tests whether REGN5678 (nezastomig) is safe and how well it works, either by itself or with an immunotherapy drug (cemiplimab). It targets adults with metastatic castration-resistant prostate cancer and certain metastatic kidney cancers that have already been treated.
Gilbert, ArizonaAges 18 years+ - NCT03977571Recruiting
Surgery plus cancer drugs for kidney cancer that spread
This trial studies whether removing the kidney tumor with “deferred cytoreductive nephrectomy” (surgery at a later time) works best for people whose metastatic kidney cancer is already present. It compares a standard treatment approach using either immunotherapy (nivolumab/ipilimumab) or a targeted pill plus immunotherapy (TKI/IO), with planned surgery afterward.
Aarhus, Central Region of DenmarkAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Birmingham, AlabamaAges 18 years+ - NCT03786796RecruitingPhase 2
Olaparib for metastatic kidney cancer with specific DNA repair gene changes
This trial tests olaparib (a pill medicine) in people with kidney cancer that has spread and specific DNA “repair” gene mutations. The goal is to see whether this targeted treatment can slow the cancer or help it respond better after prior immunotherapy or blood-vessel–blocking therapy.
Baltimore, MarylandAges 18–120 - NCT03374267Recruiting
Urologic cancer registry study
This registry study collects information from people with different types of advanced or high-risk urologic cancers. It helps doctors learn more about how these cancers are treated in real life.
Multiple LocationsAges 18 years+ - NCT00001238Recruiting
Understanding kidney cancer genes in families
This research study helps doctors understand inherited kidney cancers and related conditions that run in families. Researchers collect medical information and blood samples to identify genetic causes and improve how these conditions are diagnosed and treated.
Bethesda, MarylandAges 2 years+ - NCT07714018Recruiting
Comparing two weight loss programs for kidney cancer patients
This study tests two different weight loss programs to see which one helps prevent kidney cancer from growing in people with small kidney masses who are under active surveillance. It may help by improving overall health and potentially slowing cancer progression.
Buffalo, New YorkAges 18 years+ - NCT06344052RecruitingPhase 2
SP-002 with Vismodegib for Advanced Basal Cell Cancer
This trial tests a new drug (SP-002) combined with vismodegib for people with locally advanced basal cell carcinoma, a type of skin cancer that can't be treated with surgery or has come back after surgery. The goal is to see if this combination is safe and effective.
Phoenix, ArizonaAges 18 years+ - NCT07546383Recruiting
New Immunotherapy Combination for Advanced Head and Neck Cancer
This trial tests a new combination of two immunotherapy drugs (called iparomlimab and tuvonralimab), with or without chemotherapy, for head and neck squamous cell carcinoma that has returned or spread after previous treatment. The goal is to see if this combination can help people with this cancer live longer with fewer side effects.
Haikou, HainanAges 18–75 - NCT07278479RecruitingPhase 1/Phase 2
Study of a targeted radiation therapy for small cell lung cancer
This trial tests a new drug called MP0712 that delivers radiation directly to cancer cells that have a marker called DLL3. It is for people with small cell lung cancer or other solid tumors that express DLL3, whose cancer has come back after prior treatments.
Tampa, FloridaAges 18 years+ - NCT07124000Recruiting
T-DXd for advanced HER2-positive solid tumors
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
Birmingham, AlabamaAges 18–130 - NCT07087860RecruitingPhase 2
Plasma exchange plus targeted therapy for advanced bladder cancer
This trial tests a procedure called therapeutic plasma exchange (TPE) combined with the drugs enfortumab vedotin and pembrolizumab for people with advanced bladder cancer that has stopped responding to standard treatments. The goal is to see if TPE helps the drugs work better.
Rochester, MinnesotaAges 18 years+ - NCT07055841RecruitingPhase 2
Study of PD-L1 antibody plus chemo before surgery for head and neck cancer
This trial tests whether adding a PD-L1 antibody (Adabelimab) to standard chemotherapy before surgery can help treat advanced head and neck squamous cell carcinoma. It is for people who have not had treatment for this cancer before and are well enough to undergo the therapy.
Jinan, ShandongAges 18–85 - NCT06492460RecruitingPhase 3
Two courses of chemo-radiation after surgery for high-risk head and neck cancer
This trial tests whether giving two rounds of cisplatin chemo along with radiation after surgery can help people with high-risk head and neck squamous cell carcinoma. It is for patients who have already had surgery and whose cancer showed signs of being more aggressive.
Guangzhou, GuangdongAges 18–70 - NCT06624475RecruitingPhase 2
New immunotherapy before surgery for high-risk basal cell cancer
This trial tests if giving a combination of two immunotherapy drugs (nivolumab and relatlimab) before surgery works better than one drug alone for people with large or high-risk basal cell skin cancer that needs surgery. The goal is to shrink the cancer and make surgery easier.
Irvine, CaliforniaAges 18 years+ - NCT06623201RecruitingPhase 1
Light therapy and sonidegib for multiple BCC
This trial tests a combination of blue-light therapy (a type of photodynamic therapy) and an oral medication called sonidegib for people with multiple basal cell carcinomas (BCCs). It may be an option if you have several BCCs that are not suitable for surgery or radiation, or if you prefer not to have surgery.
Phoenix, ArizonaAges 18 years+ - NCT03741426RecruitingPhase 2
New drug combinations for kidney cancer before surgery
This trial tests new drug combinations for kidney cancer that is removable by surgery but may have spread. The goal is to see if these treatments can shrink tumors before surgery and improve outcomes.
Cambridge, EnglandAges 18 years+ - NCT01050504Recruiting
Donate blood and tissue to study recurrent or metastatic cancers
This study collects and studies blood and, when possible, small tissue samples from people with prostate or bladder/urothelial cancer that has come back or spread. The goal is to better understand these cancers and support future research that may lead to better care.
Seattle, WashingtonAges 18 years+ - NCT03288532RecruitingPhase 3
Adjuvant immunotherapy after kidney cancer surgery
This Phase 3 trial studies additional (adjuvant) treatment after kidney cancer surgery, to lower the chance the cancer comes back. It tests immunotherapy drugs (durvalumab and tremelimumab) in people whose scans show no visible remaining cancer after operation.
AberdeenAges 18 years+
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for renal cell carcinoma?
- Yes. Clin2 currently lists 529 recruiting renal cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a renal cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a renal cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.